voxelotor

01/01/2021 - "Voxelotor: A Novel Treatment for Sickle Cell Disease."
01/01/2022 - "Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years."
01/01/2023 - "Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study."
05/01/2021 - "In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin polymerisation inhibitor, was approved in the USA for the treatment of sickle cell disease in patients aged 12 years and older on the basis of HOPE trial data. "
05/01/2021 - "Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial."

07/01/2023 - "Most studies report voxelotor's significant reduction in hemolysis; however, data related to positive effects on clinical outcomes, namely Vaso-occlusive crisis (VOCs), are sparse. "
07/01/2023 - "We aimed to evaluate whether these voxelotor-induced changes can be linked to improvement of hemolysis markers in pediatric patients on voxelotor. "
01/01/2022 - "Based on its mechanism as an HbS polymerization inhibitor, voxelotor improves Hb levels and markers of hemolysis and has the potential to mitigate SCD-related complications; these results support its use in patients aged ≥4 years."
06/01/2021 - "Voxelotor also reduced markers of hemolysis but failed to reach statistically significance in current evidence. "
01/01/2019 - "All patients who received multiple doses of voxelotor for ≥28 days experienced hematologic improvements including increased Hb and reduction in hemolysis and percentage of sickled red cells, supporting the potential of voxelotor to serve as a disease-modifying therapy for SCD. "

01/01/2021 - "Our results demonstrate that 3 weeks of GBT440 treatment eliminated chronic anemia, increased left ventricular ejection fraction (LVEF) and stroke volume index, and improved right ventricular function. "
11/01/2022 - "This report provides evidence regarding the use of voxelotor in the treatment of profound anemia where other treatments could be unsafe or unavailable."
01/01/2019 - "Anemia worsened between baseline and week 24 in fewer participants in each voxelotor dose group than in those receiving placebo. "
01/01/2023 - "We report here eight patients on Voxelotor therapy, six of which showed improved hemolytic markers and anemia and demonstrated the appearance of HbD peak on the HPLC chromatogram. "
07/01/2023 - "Our recommendation remains to offer and optimize hydroxycarbamide therapy and consider voxelotor in situations with severe anemia and related sequelae affecting the brain or kidney."

07/01/2023 - "The search keywords were as follows: hemolytic anemia, SCD, voxelotor/GBT 440. "
01/01/2023 - "Voxelotor is a first-in-class HbS polymerization inhibitor approved by the US Food and Drug Administration as a treatment for SCD and by the European Medicines Agency for hemolytic anemia due to SCD. "
01/01/2021 - "Given the recency of the approval, there has not been sufficient long-term follow-up to demonstrate improvement in the chronic sequelae of sickle cell disease as a result of voxelotor-induced improvements in hemolytic anemia. "
07/01/2023 - "An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'."
05/01/2021 - "Voxelotor 1500 mg resulted in rapid and durable improvements in haemoglobin concentrations maintained over 72 weeks and has potential to address the substantial morbidity associated with haemolytic anaemia in sickle cell disease. "

01/01/2023 - "Voxelotor as a Treatment of Persistent Hypoxia in the ICU."
01/01/2019 - "Voxelotor was well tolerated with no treatment-related serious adverse events and no evidence of tissue hypoxia. "
01/01/2020 - "Accordingly, this study investigated the efficacy of an allosteric hemoglobin modulator (voxelotor) to enhance arterial oxygen saturation during low-intensity exercise in hypoxia. "
01/01/2022 - "GBT1118, a voxelotor analog, protects red blood cells from damage during severe hypoxia."
01/01/2021 - "Methods: Eight healthy subjects completed a maximal incremental exercise test in hypoxia (FIO2: 0.125) and normoxia (FIO2: 0.21) before (Day 1) and after (Day 15) daily ingestion of 900 mg of voxelotor (an oxygen/Hb affinity modulator). "